2186:HKEXLuye Pharma Group Ltd. Analysis

Luye Pharma is trading at HK$2.51, well below its 20‑day SMA of 2.56, 50‑day SMA of 2.74 and 200‑day SMA of 3.22, indicating a bearish price trend despite a neutral RSI of 43. The MACD shows a subtle bullish signal (histogram positive) but the line remains negative, suggesting limited short‑term upside. The stock sits above its nearest support at HK$2.36 and below resistance at HK$2.77, with volume trending upward, which could provide a catalyst for a bounce. Fundamentally, the company appears undervalued: a DCF fair value of HK$5.73 implies a 64% upside, its PE of 20.9 is below the industry average of 26.4, and the PB of 0.57 signals a cheap balance sheet. However, concerns remain – a high 30‑day volatility of 32.5%, a max drawdown near 46%, a debt‑to‑equity ratio of 71.8% and negative free cash flow raise red flags. Recent governance tightening may mitigate some operational risk, but the overall risk profile stays elevated.